5.26
전일 마감가:
$5.17
열려 있는:
$5.16
하루 거래량:
1.31M
Relative Volume:
1.18
시가총액:
$315.05M
수익:
-
순이익/손실:
$-44.80M
주가수익비율:
-7.0133
EPS:
-0.75
순현금흐름:
$-30.67M
1주 성능:
+9.36%
1개월 성능:
+21.48%
6개월 성능:
-11.30%
1년 성능:
+25.54%
Aldeyra Therapeutics Inc Stock (ALDX) Company Profile
명칭
Aldeyra Therapeutics Inc
전화
781-761-4904
주소
131 HARTWELL AVENUE, LEXINGTON, MA
ALDX을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
![]()
ALDX
Aldeyra Therapeutics Inc
|
5.26 | 312.65M | 0 | -44.80M | -30.67M | -0.75 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
366.54 | 98.88B | 11.42B | 3.64B | 3.50B | 13.99 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
563.00 | 58.84B | 14.21B | 4.46B | 3.56B | 39.68 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
438.93 | 56.12B | 2.46B | -319.09M | -52.09M | -2.47 |
![]()
ARGX
Argen X Se Adr
|
661.83 | 41.20B | 3.05B | 1.28B | -614.78M | 19.58 |
![]()
ONC
Beone Medicines Ltd Adr
|
288.18 | 35.49B | 3.81B | -644.79M | -669.77M | -6.24 |
Aldeyra Therapeutics Inc Stock (ALDX) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2024-04-03 | 업그레이드 | Oppenheimer | Perform → Outperform |
2024-04-02 | 재개 | H.C. Wainwright | Buy |
2022-04-27 | 재개 | H.C. Wainwright | Buy |
2021-02-08 | 개시 | H.C. Wainwright | Buy |
2020-12-16 | 개시 | Berenberg | Buy |
2020-10-30 | 개시 | Jefferies | Buy |
2020-10-16 | 개시 | BTIG Research | Buy |
2020-09-22 | 개시 | Alliance Global Partners | Buy |
2020-05-12 | 개시 | Oppenheimer | Outperform |
2018-12-04 | 개시 | Citigroup | Buy |
2018-09-26 | 재확인 | Cantor Fitzgerald | Overweight |
2018-09-13 | 개시 | Janney | Buy |
2018-01-26 | 개시 | Seaport Global Securities | Buy |
2016-09-26 | 개시 | H.C. Wainwright | Buy |
2016-07-01 | 개시 | Stifel | Buy |
2015-07-01 | 개시 | Canaccord Genuity | Buy |
2015-03-25 | 개시 | Chardan Capital Markets | Buy |
2015-03-20 | 재확인 | H.C. Wainwright | Buy |
2014-11-18 | 개시 | H.C. Wainwright | Buy |
2014-06-19 | 개시 | Aegis Capital | Buy |
모두보기
Aldeyra Therapeutics Inc 주식(ALDX)의 최신 뉴스
Aldeyra price target raised to $9 from $6 at Jones Trading on FDA acceptance - Investing.com Canada
Aldeyra Therapeutics to Participate in the H.C. Wainwright 5th A - GuruFocus
Aldeyra CEO to Share Exclusive Ophthalmology Pipeline Updates at H.C. Wainwright Conference - Stock Titan
Why is Aldeyra Therapeutics Inc. stock attracting strong analyst attentionTremendous portfolio expansion - Jammu Links News
Is Aldeyra Therapeutics Inc. a good long term investmentBuild a portfolio that outperforms the market - Jammu Links News
What makes Aldeyra Therapeutics Inc. stock price move sharplyFree Trend-Following Techniques - Jammu Links News
How does Aldeyra Therapeutics Inc. generate profit in a changing economyPowerful profit generation - Jammu Links News
Should I hold or sell Aldeyra Therapeutics Inc. stock in 2025Strongest growth potential - Jammu Links News
When is Aldeyra Therapeutics Inc. stock expected to show significant growthSky-high profits - Jammu Links News
Published on: 2025-08-02 20:17:22 - beatles.ru
Is Aldeyra Therapeutics Inc. stock overvalued or undervaluedEarnings Report Alerts With Proven Results - Jammu Links News
What are analysts’ price targets for Aldeyra Therapeutics Inc. in the next 12 monthsWealth Building Insights That Work - Jammu Links News
How many analysts rate Aldeyra Therapeutics Inc. as a “Buy”AI Powered Entry Points That Work - Jammu Links News
Exploring US High Growth Tech Stocks For July 2025 - simplywall.st
Why Aldeyra Therapeutics Inc. stock attracts strong analyst attentionConsistent Gain Investment Strategies Emerge - metal.it
Published on: 2025-07-29 20:51:08 - metal.it
Trendline Breach Raises Concern for Aldeyra Therapeutics Inc. InvestorsCommunity Verified Stock Suggestions Drive Volume - metal.it
Why did ALDX's EPS remain stagnant in recent quarters? - AInvest
How Aldeyra Therapeutics Inc. stock performs during market volatilityFundamental Growth Stock Analysis Shows Strength - metal.it
How volatile is Aldeyra Therapeutics Inc. stock compared to the marketUnmatched market performance - Jammu Links News
What makes Aldeyra Therapeutics Inc. stock attractive to long term investorsAnalyst Grade Signals - metal.it
What is the risk reward ratio of investing in Aldeyra Therapeutics Inc. stockCapitalize on strategic market trends - Jammu Links News
What are Aldeyra Therapeutics Inc. company’s key revenue driversUnlock high-yield investment opportunities - jammulinksnews.com
Aldeyra Therapeutics receives orphan designation for ADX-2191 from EMA - Ophthalmology Times
Aldeyra Therapeutics Receives Orphan Designation from the Europe - GuruFocus
What drives Aldeyra Therapeutics Inc. stock priceFree Risk Assessment Services - printweek.in
What analysts say about Aldeyra Therapeutics Inc. stockExceptional gains - Autocar Professional
EMA grants orphan designation to ADX-2191 (Aldeyra Therapeutics) for inherited retinal dystrophies - Ophthalmology Times Europe
EMA grants orphan designation for Aldeyra’s eye treatment By Investing.com - Investing.com India
EMA grants orphan designation for Aldeyra’s eye treatment - Investing.com
Breakthrough: Aldeyra's Eye Drug Gets EU Orphan Status for Treating Incurable Genetic Blindness - Stock Titan
Published on: 2025-07-23 18:29:07 - Autocar Professional
Aldeyra Therapeutics Inc. Stock Analysis and ForecastSuperior returns - jammulinksnews.com
Aldeyra Therapeutics Inc (ALDX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):